Ted M Dawson

List of PR Articles by Year in descending order

Source: //exaly.com/author-pdf/5486853/publications.pdf

Version: 2025-02-01

358 PR articles	63,698 PR citations	315 121 PR h-index	448 246 g-index
413 documents	80474 doc citations	312 135 h-index	73813 citing authors

#	Article	IF	PR Citations
1	Interspecies chimerism with human embryonic stem cells generates functional human dopamine neurons at low efficiency. Stem Cell Reports, 2024, 19, 54-67.	4.5	5
2	Protein Translation in the Pathogenesis of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2024, 25, 2393.	4.5	7
3	Blocking the <scp>Selfâ€Destruct</scp> Program of Dopamine Neurons through <scp>Macrophage Migration Inhibitory Factor</scp> Nuclease Inhibition. Movement Disorders, 2024, 39, 644-650.	4.6	2
4	Poly(<scp>ADP</scp>â€ribose) mediates bioenergetic defects and redox imbalance in neurons following oxygen and glucose deprivation. FASEB Journal, 2024, 38, .	0.7	10
5	Parthanatos: Mechanisms, modulation, and therapeutic prospects in neurodegenerative disease and stroke. Biochemical Pharmacology, 2024, 228, 116174.	5.2	39
6	Aplp1 interacts with Lag3 to facilitate transmission of pathologic Î±-synuclein. Nature Communications, 2024, 15, .	13.9	32
7	Enhancing mitochondrial proteolysis alleviates alpha-synuclein-mediated cellular toxicity. Npj Parkinson's Disease, 2024, 10, .	7.2	13
8	Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release. Journal of Cell Science, 2024, 137, .	2.5	5
9	Poly ADP-ribose signaling is dysregulated in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.6	11
10	The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinsonâ€™s disease. Science Translational Medicine, 2023, 15, .	12.7	26
11	Farnesol prevents aging-related muscle weakness in mice through enhanced farnesylation of Parkin-interacting substrate. Science Translational Medicine, 2023, 15, .	12.7	17
12	<scp>PARIS</scp> undergoes liquidâ€“liquid phase separation and poly(<scp>ADP</scp>â€ribose)â€mediated solidification. EMBO Reports, 2023, 24, .	5.2	8
13	Enhanced mTORC1 signaling and protein synthesis in pathologic Î±-synuclein cellular and animal models of Parkinsonâ€™s disease. Science Translational Medicine, 2023, 15, .	12.7	49
14	CYFIP1 Dosages Exhibit Divergent Behavioral Impact via Diametric Regulation of NMDA Receptor Complex Translation in Mouse Models of Psychiatric Disorders. Biological Psychiatry, 2022, 92, 815-826.	5.5	17
15	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	8.5	51
16	Waiting for PARISâ€”A Biological Target in Search of a Drug. Journal of Parkinson's Disease, 2022, 12, 95-103.	3.4	3
17	Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver. IScience, 2022, 25, 103996.	3.6	37
18	Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinsonâ€™s disease. Science Advances, 2022, 8, .	11.0	23

#	Article	IF	PR Citations
19	STING mediates neurodegeneration and neuroinflammation in nigrostriatal Î±-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.6	174
20	A high-affinity cocaine binding site associated with the brain acid soluble protein 1. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.6	7
21	Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease. Movement Disorders, 2022, 37, 1454-1464.	4.6	27
22	PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinsonâ€™s disease. Cell, 2022, 185, 1943-1959.e21.	34.1	97
23	Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinsonâ€™s disease. Neuron, 2022, 110, 2422-2437.e9.	11.1	171
24	AAAâ€‰+â€‰ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1. Nature Communications, 2022, 13, .	13.9	7
25	Amelioration of pathologic Î±-synuclein-induced Parkinsonâ€™s disease by irisin. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.6	105
26	Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins. Science Translational Medicine, 2022, 14, .	12.7	21
27	The Absence of Parkin Does Not Promote Dopamine or Mitochondrial Dysfunction in PolgA^{D257A/D257A}Mitochondrial Mutator Mice. Journal of Neuroscience, 2022, 42, 9263-9277.	3.7	19
28	Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinsonâ€™s Disease. CNS Drugs, 2022, 36, 1249-1267.	6.5	7
29	Mass spectrometryâ€based proteomics analysis of human globus pallidus from progressive supranuclear palsy patients discovers multiple disease pathways. Clinical and Translational Medicine, 2022, 12, .	5.7	24
30	Nanozyme scavenging ROS for prevention of pathologic Î±-synuclein transmission in Parkinsonâ€™s disease. Nano Today, 2021, 36, 101027.	10.0	128
31	Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2021, 29, 958-968.	1.8	24
32	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	26.1	368
33	Lymphocyte Activation Gene 3 (Lag3) Contributes to Î±-Synucleinopathy in Î±-Synuclein Transgenic Mice. Frontiers in Cellular Neuroscience, 2021, 15, .	3.5	46
34	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. JAMA Neurology, 2021, 78, 312.	15.1	123
35	The cell biology of Parkinsonâ€™s disease. Journal of Cell Biology, 2021, 220, .	5.5	135
36	AIF3 splicing switch triggers neurodegeneration. Molecular Neurodegeneration, 2021, 16, .	14.6	8

#	Article	IF	PR Citations
37	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, .	5.0	160
38	Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 469-480.	1.1	15
39	Targeting Parthanatos in Ischemic Stroke. Frontiers in Neurology, 2021, 12, .	2.4	51
40	Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons. STAR Protocols, 2021, 2, 100405.	1.2	11
41	Mechanistic basis for receptor-mediated pathological Î±-synuclein fibril cell-to-cell transmission in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.6	101
42	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in Î±-Synuclein-Based Mouse Models of Parkinsonâ€™s Disease. Journal of Proteome Research, 2021, 20, 3428-3443.	3.5	52
43	Neurodegenerative disorders and gut-brain interactions. Journal of Clinical Investigation, 2021, 131, .	10.7	95
44	Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 1834-1848.	6.2	33
45	PARIS farnesylation prevents neurodegeneration in models of Parkinsonâ€™s disease. Science Translational Medicine, 2021, 13, .	12.7	58
46	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	2.6	13
47	Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. Brain, 2021, 144, 3674-3691.	8.5	24
48	LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8. Cells, 2021, 10, 203.	4.8	1
49	USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing. Nucleic Acids Research, 2021, 49, 11083-11102.	15.7	25
50	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. Pharmacological Reviews, 2021, 73, 1204-1268.	16.0	29
51	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinsonâ€™s disease. Neuron, 2021, 109, 3758-3774.e11.	11.1	46
52	Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-Î³ associated gene regulation. Scientific Reports, 2021, 11, .	3.5	14
53	Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. ENeuro, 2021, 8, ENEURO.0310-21.2021.	2.1	12
54	Recent advances in preventing neurodegenerative diseases. Faculty Reviews, 2021, 10, .	4.2	15

#	Article	IF	PR Citations
55	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	8.5	225
56	Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. Cell Stem Cell, 2020, 27, 633-645.e7.	16.8	54
57	Meta-Analysis of the Alzheimerâ€™s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908.	6.4	266
58	Determinants of seeding and spreading of Î±-synuclein pathology in the brain. Science Advances, 2020, 6, .	11.0	101
59	Microglia and astrocyte dysfunction in parkinson's disease. Neurobiology of Disease, 2020, 144, 105028.	5.2	331
60	Molecular Mediation of Prion-like Î±-Synuclein Fibrillation from Toxic PFFs to Nontoxic Species. ACS Applied Bio Materials, 2020, 3, 6096-6102.	4.8	14
61	Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. Stem Cell Reports, 2020, 15, 629-645.	4.5	71
62	AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF. Cell Reports, 2020, 33, 108329.	6.4	18
63	Development of a novel method for the quantification of tyrosine 39 phosphorylated Î±- and Î²-synuclein in human cerebrospinal fluid. Clinical Proteomics, 2020, 17, .	3.0	12
64	PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Molecular Neurodegeneration, 2020, 15, .	14.6	81
65	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, .	14.6	432
66	Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke. PLoS ONE, 2020, 15, e0231978.	2.4	13
67	NLRP3 inflammasome activation in dopamine neurons contributes to neurodegeneration in Parkinsonâ€™s Disease. FASEB Journal, 2020, 34, 1-1.	0.7	7
68	Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain. Bio-protocol, 2020, 10, .	0.5	2
69	Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2019, 7, .	5.0	58
70	Transneuronal Propagation of Pathologic Î±-Synuclein from the Gut to the Brain Models Parkinsonâ€™s Disease. Neuron, 2019, 103, 627-641.e7.	11.1	1,215
71	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinsonâ€™s disease. Brain, 2019, 142, 2380-2401.	8.5	66
72	The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. Movement Disorders, 2019, 34, 959-969.	4.6	88

#	Article	IF	PR Citations
73	Fyn kinase regulates misfolded Î±-synuclein uptake and NLRP3 inflammasome activation in microglia. Journal of Experimental Medicine, 2019, 216, 1411-1430.	9.4	236
74	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	5.2	38
75	Assessment of APOE in atypical parkinsonism syndromes. Neurobiology of Disease, 2019, 127, 142-146.	5.2	26
76	Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities. ENeuro, 2019, 6, ENEURO.0148-19.2019.	2.1	19
77	Promising disease-modifying therapies for Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, .	12.7	59
78	Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiology of Aging, 2019, 76, 214.e1-214.e9.	3.4	44
79	Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. Stem Cells Translational Medicine, 2019, 8, 112-123.	4.2	48
80	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.4	14
81	The AAAâ€‰+â€‰ATPase Thorase is neuroprotective against ischemic injury. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1836-1848.	4.8	15
82	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 29-36.	2.6	137
83	DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders. Translational Psychiatry, 2018, 8, .	5.5	41
84	A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. Brain, 2018, 141, 651-661.	8.5	59
85	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1635-1640.	7.6	96
86	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	13.7	5,678
87	GBA1 deficiency negatively affects physiological Î±-synuclein tetramers and related multimers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 798-803.	7.6	166
88	Opportunities for the repurposing of PARP inhibitors for the therapy of nonâ€oncological diseases. British Journal of Pharmacology, 2018, 175, 192-222.	6.5	192
89	Domainâ€specific cognitive impairment in nonâ€demented Parkinson's disease psychosis. International Journal of Geriatric Psychiatry, 2018, 33, .	2.4	11
90	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 47, 50-56.	2.6	18

#	Article	IF	PR Citations
91	Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Movement Disorders Clinical Practice, 2018, 5, 31-38.	1.5	10
92	Animal models of neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1370-1379.	17.1	513
93	Poly(ADP-ribose) drives pathologic Î±-synuclein neurodegeneration in Parkinsonâ€™s disease. Science, 2018, 362, .	36.4	441
94	The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. Juntendo Medical Journal, 2018, 64, 17-30.	0.2	0
95	Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease. Cell Metabolism, 2018, 28, 588-604.e5.	26.2	254
96	Î±-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Molecular Neurodegeneration, 2018, 13, .	14.6	181
97	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Molecular Neurodegeneration, 2018, 13, .	14.6	98
98	Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism and Related Disorders, 2018, 55, 8-14.	2.6	43
99	Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 2017, 541, 481-487.	38.7	6,890
100	Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annual Review of Pharmacology and Toxicology, 2017, 57, 437-454.	12.0	151
101	PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Reports, 2017, 18, 918-932.	6.4	173
102	Precision therapy for a new disorder of AMPA receptor recycling due to mutations in ATAD1. Neurology: Genetics, 2017, 3, .	2.9	48
103	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Molecular Neurodegeneration, 2017, 12, .	14.6	70
104	Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes. Experimental Neurology, 2017, 298, 191-201.	4.1	64
105	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	18.4	167
106	Activation mechanisms of the E3 ubiquitin ligase parkin. Biochemical Journal, 2017, 474, 3075-3086.	3.9	52
107	Toward the human cellular microRNAome. Genome Research, 2017, 27, 1769-1781.	4.6	165
108	Two approaches reveal a new paradigm of â€˜switchable or genetics-influenced allele-specific DNA methylationâ€™ with potential in human disease. Cell Discovery, 2017, 3, .	9.6	26

#	Article	IF	PR Citations
109	Heterozygous PINK1 p.G411S increases risk of Parkinsonâ€™s disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117.	8.5	129
110	Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1982-1993.	4.8	28
111	c-Abl and Parkinsonâ€™s Disease: Mechanisms and Therapeutic Potential. Journal of Parkinson's Disease, 2017, 7, 589-601.	3.4	84
112	Overexpression of Parkinsonâ€™s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and Î±-Synuclein Pathology. ENeuro, 2017, 4, ENEURO.0004-17.2017.	2.1	37
113	The NINDS Parkinson's disease biomarkers program. Movement Disorders, 2016, 31, 915-923.	4.6	107
114	LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. Journal of Chemical Neuroanatomy, 2016, 76, 90-97.	2.0	42
115	Pathological Î±-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 2016, 353, .	36.4	649
116	Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. Parkinsonism and Related Disorders, 2016, 33, 107-114.	2.6	23
117	Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 33, 102-106.	2.6	8
118	A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science, 2016, 354, .	36.4	359
119	LRRK2 pathobiology in Parkinson's disease â€“ virtual inclusion. Journal of Neurochemistry, 2016, 139, 75-76.	3.9	6
120	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	15.1	220
121	Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nature Communications, 2016, 7, .	13.9	70
122	Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. Science Translational Medicine, 2016, 8, .	12.7	87
123	Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiology of Disease, 2016, 94, 55-62.	5.2	62
124	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	14.0	4,989
125	GBA Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 95-102.	4.6	195
126	Activation of tyrosine kinase c-Abl contributes to Î±-synucleinâ€“induced neurodegeneration. Journal of Clinical Investigation, 2016, 126, 2970-2988.	10.7	166

#	Article	IF	PR Citations
127	Adult Conditional Knockout of PGC-1Î± Leads to Loss of Dopamine Neurons. ENeuro, 2016, 3, ENEURO.0183-16.2016.	2.1	95
128	High-Content Genome-Wide RNAi Screen RevealsCCR3as a Key Mediator of Neuronal Cell Death. ENeuro, 2016, 3, ENEURO.0185-16.2016.	2.1	19
129	(Pathoâ€)physiological relevance of <scp>PINK</scp> 1â€dependent ubiquitin phosphorylation. EMBO Reports, 2015, 16, 1114-1130.	5.2	176
130	Lysosomal Enzyme Glucocerebrosidase Protects against AÎ²1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854.	2.4	17
131	PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980.	1.0	50
132	TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinsonâ€™s disease via CNTF. Brain, 2015, 138, 3610-3622.	8.5	126
133	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11696-11701.	7.6	240
134	Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Human Molecular Genetics, 2014, 23, 2055-2077.	3.0	121
135	Abberant protein synthesis in G2019S LRRK2DrosophilaParkinson disease-related phenotypes. Fly, 2014, 8, 165-169.	2.1	20
136	<scp>M</scp>sp1/<scp>ATAD</scp>1 maintains mitochondrial function by facilitating the degradation of mislocalized tailâ€anchored proteins. EMBO Journal, 2014, 33, 1548-1564.	7.4	219
137	Protein Microarray Characterization of the S-Nitrosoproteome. Molecular and Cellular Proteomics, 2014, 13, 63-72.	3.0	58
138	LRRK2 pathobiology in Parkinson's disease. Journal of Neurochemistry, 2014, 131, 554-565.	3.9	150
139	Proneural Transcription Factor Atoh1 Drives Highly Efficient Differentiation of Human Pluripotent Stem Cells Into Dopaminergic Neurons. Stem Cells Translational Medicine, 2014, 3, 888-898.	4.2	43
140	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	15.1	372
141	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinsonâ€™s Disease. Cell, 2014, 157, 472-485.	34.1	265
142	Parkin and PINK1: much more than mitophagy. Trends in Neurosciences, 2014, 37, 315-324.	9.8	341
143	Early-onset Parkinson's disease due to PINK1 p.Q456X mutation â€“ Clinical and functional study. Parkinsonism and Related Disorders, 2014, 20, 1274-1278.	2.6	48
144	Parkinâ€independent mitophagy requires <scp>D</scp>rp1 and maintains the integrity of mammalian heart and brain. EMBO Journal, 2014, 33, 2798-2813.	7.4	414

#	Article	IF	PR Citations
145	Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10209-10214.	7.6	297
146	Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinsonâ€™s-like movement disorder. Nature Communications, 2014, 5, .	13.9	144
147	Ganglioside Regulation of AMPA Receptor Trafficking. Journal of Neuroscience, 2014, 34, 13246-13258.	3.7	59
148	MiR-223 regulates the differentiation of immature neurons. Molecular and Cellular Therapies, 2014, 2, 18.	0.0	29
149	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiology of Disease, 2014, 71, 345-358.	5.2	71
150	Parthanatos: mitochondrialâ€linked mechanisms and therapeutic opportunities. British Journal of Pharmacology, 2014, 171, 2000-2016.	6.5	525
151	The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Scientific Reports, 2014, 4, .	3.5	223
152	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nature Neuroscience, 2013, 16, 1392-1400.	17.1	207
153	Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Molecular Aspects of Medicine, 2013, 34, 1066-1087.	9.6	158
154	Usp16: key controller of stem cells in Down syndrome. EMBO Journal, 2013, 32, 2788-2789.	7.4	9
155	New synaptic and molecular targets for neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 51-60.	4.6	38
156	Sulfhydration mediates neuroprotective actions of parkin. Nature Communications, 2013, 4, .	13.9	320
157	The interplay of microRNA and neuronal activity in health and disease. Frontiers in Cellular Neuroscience, 2013, 7, .	3.5	52
158	LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization. PLoS ONE, 2013, 8, e77198.	2.4	73
159	Linked Clinical Trials â€“ The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments. Journal of Parkinson's Disease, 2013, 3, 231-239.	3.4	39
160	Nitric Oxide Synthase Inhibitors. CNS Drugs, 2012, 6, 351-357.	6.5	0
161	ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2. Journal of Neuroscience, 2012, 32, 3877-3886.	3.7	98
162	Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Human Molecular Genetics, 2012, 21, 163-174.	3.0	38

#	Article	IF	PR Citations
163	Animal Models of Parkinson's Disease: Vertebrate Genetics. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009324-a009324.	6.7	106
164	Neurodegenerative phenotypes in an A53T Â-synuclein transgenic mouse model are independent of LRRK2. Human Molecular Genetics, 2012, 21, 2420-2431.	3.0	96
165	MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18962-18967.	7.6	269
166	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends in Pharmacological Sciences, 2012, 33, 365-373.	11.8	71
167	Botch Promotes Neurogenesis by Antagonizing Notch. Developmental Cell, 2012, 22, 707-720.	7.8	69
168	Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Annals of Neurology, 2012, 71, 370-384.	6.3	288
169	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, .	12.7	478
170	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinsonâ€™s Disease-Related Toxicity in Human Neurons. ACS Chemical Biology, 2011, 6, 1021-1028.	3.7	142
171	PARIS (ZNF746) Repression of PGC-1Î± Contributes to Neurodegeneration in Parkinson's Disease. Cell, 2011, 144, 689-702.	34.1	901
172	The AAA+ ATPase Thorase Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior. Cell, 2011, 145, 284-299.	34.1	104
173	Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1â€“Dependent Cell Death (Parthanatos). Science Signaling, 2011, 4, .	5.5	428
174	MicroRNAs in Parkinson's disease. Journal of Chemical Neuroanatomy, 2011, 42, 127-130.	2.0	164
175	Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE, 2011, 6, e18568.	2.4	363
176	Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nature Medicine, 2011, 17, 692-699.	39.5	206
177	Recent Advances in the Genetics of Parkinson's Disease. Annual Review of Genomics and Human Genetics, 2011, 12, 301-325.	6.8	400
178	A perfect â€œMatchâ€•for in vitro human disease modeling and autologous cell-based transplantation therapy: Generating genetically identical Parkinson's disease and control pluripotent stem cells by precise gene targeting. Movement Disorders, 2011, 26, 1804-1804.	4.6	0
179	Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14103-14108.	7.6	251
180	Enhanced Autophagy from Chronic Toxicity of Iron and Mutant A53T Î±-Synuclein. Journal of Biological Chemistry, 2011, 286, 33380-33389.	2.2	85

#	Article	IF	PR Citations
181	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 2011, 20, 3933-3942.	3.0	131
182	Resistance to MPTP-Neurotoxicity in Î±-Synuclein Knockout Mice Is Complemented by Human Î±-Synuclein and Associated with Increased Î²-Synuclein and Akt Activation. PLoS ONE, 2011, 6, e16706.	2.4	61
183	Neuronal Activity Regulates Hippocampal miRNA Expression. PLoS ONE, 2011, 6, e25068.	2.4	50
184	The role of parkin in familial and sporadic Parkinson's disease. Movement Disorders, 2010, 25, .	4.6	341
185	Contributions of poly(ADPâ€ribose) polymeraseâ€1 and â€2 to nuclear translocation of apoptosisâ€inducing factor and injury from focal cerebral ischemia. Journal of Neurochemistry, 2010, 113, 1012-1022.	3.9	56
186	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	39.5	358
187	NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. Journal of Clinical Investigation, 2010, 120, 2446-2456.	10.7	44
188	Synphilin-1 attenuates neuronal degeneration in the A53T Â-synuclein transgenic mouse model. Human Molecular Genetics, 2010, 19, 2087-2098.	3.0	81
189	Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2. Journal of Biological Chemistry, 2010, 285, 29569-29576.	2.2	55
190	Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16691-16696.	7.6	266
191	PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 378-383.	7.6	1,553
192	Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R215-R221.	2.4	20
193	GTPase Activity Plays a Key Role in the Pathobiology of LRRK2. PLoS Genetics, 2010, 6, e1000902.	3.3	190
194	Genetic Animal Models of Parkinson's Disease. Neuron, 2010, 66, 646-661.	11.1	778
195	Functional Identification of Neuroprotective Molecules. PLoS ONE, 2010, 5, e15008.	2.4	33
196	S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4900-4905.	7.6	150
197	CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2897-2902.	7.6	206
198	Outer Mitochondrial Membrane Localization of Apoptosis-Inducing Factor: Mechanistic Implications for Release. ASN Neuro, 2009, 1, AN20090046.	3.4	77

#	Article	IF	PR Citations
199	Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radical Biology and Medicine, 2009, 47, 1049-1056.	3.8	57
200	Understanding microRNAs in neurodegeneration. Nature Reviews Neuroscience, 2009, 10, 837-841.	24.7	265
201	Calpain activation is not required for AIF translocation in PARPâ€1â€dependent cell death (parthanatos). Journal of Neurochemistry, 2009, 110, 687-696.	3.9	96
202	Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine). Journal of Neuroscience, 2009, 29, 15846-15850.	3.7	116
203	Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos. Experimental Neurology, 2009, 218, 193-202.	4.1	366
204	SnapShot: Pathogenesis of Parkinson's Disease. Cell, 2009, 139, 440.e1-440.e2.	34.1	12
205	Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With Î±-Synuclein Inclusions. Journal of Neuropathology and Experimental Neurology, 2009, 68, 785-796.	1.8	29
206	Abnormal Localization of Leucine-Rich Repeat Kinase 2 to the Endosomal-Lysosomal Compartment in Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 994-1005.	1.8	75
207	Role of Tuberin in Neuronal Degeneration. Neurochemical Research, 2008, 33, 1113-1116.	3.5	11
208	Value of genetic models in understanding the cause and mechanisms of Parkinsonâ€™s disease. Current Neurology and Neuroscience Reports, 2008, 8, 288-296.	4.6	43
209	Morphometry of the human substantia nigra in ageing and Parkinsonâ€™s disease. Acta Neuropathologica, 2008, 115, 461-470.	9.3	172
210	Mitochondrial and Nuclear Cross Talk in Cell Death. Annals of the New York Academy of Sciences, 2008, 1147, 233-241.	4.1	339
211	Parkin mediates the degradationâ€independent ubiquitination of Hsp70. Journal of Neurochemistry, 2008, 105, 1806-1819.	3.9	103
212	Non-autonomous cell death in Parkinson's disease. Lancet Neurology, The, 2008, 7, 474-475.	18.4	17
213	Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Human Molecular Genetics, 2008, 17, 2570-2582.	3.0	147
214	Advances in Neuronal Cell Death 2007. Stroke, 2008, 39, 286-288.	6.0	44
215	The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2. Journal of Neuroscience, 2008, 28, 3384-3391.	3.7	187
216	Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Research, 2008, 36, 6959-6976.	15.7	391

#	Article	IF	PR Citations
217	Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Human Molecular Genetics, 2008, 17, 431-439.	3.0	413
218	Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents. Journal of Biological Chemistry, 2007, 282, 16441-16453.	2.2	236
219	The Roles of Kinases in Familial Parkinson's Disease. Journal of Neuroscience, 2007, 27, 11865-11868.	3.7	52
220	DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14807-14812.	7.6	452
221	Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced Solubility Alterations. Journal of Biological Chemistry, 2007, 282, 12310-12318.	2.2	78
222	Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics, 2007, 16, 223-232.	3.0	571
223	Parkinson's disease genetic mutations increase cell susceptibility to stress: Mutant Î±-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiology of Aging, 2007, 28, 1709-1717.	3.4	55
224	A Hierarchical NGF Signaling Cascade Controls Ret-Dependent and Ret-Independent Events during Development of Nonpeptidergic DRG Neurons. Neuron, 2007, 54, 739-754.	11.1	238
225	Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. Journal of Neurochemistry, 2007, 100, 368-381.	3.9	108
226	Localization of Parkinsonâ€™s disease-associated LRRK2 in normal and pathological human brain. Brain Research, 2007, 1155, 208-219.	2.5	141
227	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiology of Disease, 2007, 26, 312-322.	5.2	66
228	A Nitric Oxide Signaling Pathway Controls CREB-Mediated Gene Expression in Neurons. Molecular Cell, 2006, 21, 283-294.	13.4	229
229	Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiology of Aging, 2006, 27, 524-529.	3.4	137
230	Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation, 2006, 116, 1744-1754.	10.7	574
231	Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience, 2006, 9, 1231-1233.	17.1	607
232	Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3887-3889.	7.6	232
233	Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18314-18319.	7.6	697
234	Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate. Journal of Biological Chemistry, 2006, 281, 16193-16196.	2.2	94

#	Article	IF	PR Citations
235	Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of Â-Synucleinopathy. Journal of Neuroscience, 2006, 26, 3685-3696.	3.7	87
236	Poly(ADP-ribose) (PAR) polymer is a death signal. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18308-18313.	7.6	612
237	Failures and Successes of Clinical Trials for Parkinson Disease Treatments. Retina, 2005, 25, S75-S77.	1.8	2
238	Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. Journal of Neurochemistry, 2005, 93, 422-431.	3.9	117
239	Neurotoxicity and behavioral deficits associated with Septinâ€ƒ5 accumulation in dopaminergic neurons. Journal of Neurochemistry, 2005, 94, 1040-1053.	3.9	68
240	The involvement of nitric oxide in the enhanced expression of Î¼ -opioid receptors during intestinal inflammation in mice. British Journal of Pharmacology, 2005, 145, 758-766.	6.5	30
241	Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Human Molecular Genetics, 2005, 14, 2571-2586.	3.0	218
242	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Human Molecular Genetics, 2005, 14, 71-84.	3.0	238
243	Bcl-x Is Required for Proper Development of the Mouse Substantia Nigra. Journal of Neuroscience, 2005, 25, 6721-6728.	3.7	167
244	Sâ€Nitrosylation in Parkinson's Disease and Related Neurodegenerative Disorders. Methods in Enzymology, 2005, , 139-150.	2.1	41
245	Identification and Evaluation of NOâ€Regulated Genes by Differential Analysis of Primary cDNA Library Expression (DAzLE). Methods in Enzymology, 2005, , 359-368.	2.1	1
246	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18676-18681.	7.6	397
247	Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation. Journal of Neuroscience, 2005, 25, 2002-2009.	3.7	521
248	Aggregation promoting C-terminal truncation of Î±-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2162-2167.	7.6	455
249	Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death. Journal of Neuroscience, 2005, 25, 7968-7978.	3.7	232
250	Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Human Molecular Genetics, 2005, 14, 3885-3897.	3.0	203
251	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Human Molecular Genetics, 2005, 14, 2063-2073.	3.0	392
252	Â-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells. Journal of Neuroscience, 2005, 25, 5544-5552.	3.7	259

#	Article	IF	PR Citations
253	MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE. Annual Review of Neuroscience, 2005, 28, 57-87.	11.4	1,182
254	Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16842-16847.	7.6	1,181
255	Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Molecular Brain Research, 2005, 134, 103-108.	2.6	78
256	The 350-fold compacted Fugu parkin gene is structurally and functionally similar to human Parkin. Gene, 2005, 346, 97-104.	2.4	6
257	To die or grow: Parkinson's disease and cancer. Trends in Neurosciences, 2005, 28, 348-352.	9.8	118
258	AÎ² deposition is associated with enhanced cortical Î±-synuclein lesions in Lewy body diseases. Neurobiology of Aging, 2005, 26, 1183-1192.	3.4	208
259	Recent advances in our understanding of Parkinson's disease. Drug Discovery Today Disease Mechanisms, 2005, 2, 427-433.	1.3	14
260	Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacological Research, 2005, 52, 5-14.	9.4	224
261	Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Human Molecular Genetics, 2005, 14, 3801-3811.	3.0	333
262	Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17699-17704.	7.6	315
263	Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10744-10749.	7.6	332
264	Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 647-652.	7.6	32
265	Identification and analysis of plasticity-induced late-response genes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2145-2150.	7.6	59
266	PARPâ€1 gene disruption in mice preferentially protects males from perinatal brain injury. Journal of Neurochemistry, 2004, 90, 1068-1075.	3.9	279
267	Deadly Conversations: Nuclear-Mitochondrial Cross-Talk. Journal of Bioenergetics and Biomembranes, 2004, 36, 287-294.	2.7	177
268	Parkin-associated Parkinsonâ€™s disease. Cell and Tissue Research, 2004, 318, 175-184.	2.7	132
269	Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Annals of Medicine, 2004, 36, 315-320.	4.1	125
270	Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death. Journal of Neuroscience, 2004, 24, 10963-10973.	3.7	273

#	Article	IF	PR Citations
271	Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends in Pharmacological Sciences, 2004, 25, 259-264.	11.8	440
272	CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Human Molecular Genetics, 2004, 13, 703-714.	3.0	679
273	Astroglia Induce Cytotoxic Effects on Brain Tumors via a Nitric Oxide-Dependent Pathway Both in Vitro and in Vivo. Neurosurgery, 2004, 54, 1231-1238.	1.9	13
274	What have Genetically Engineered Mice Taught Us About Ischemic Injury?. Current Molecular Medicine, 2004, 4, 207-225.	2.2	14
275	Role for the Ubiquitin-Proteasome System in Parkinson's Disease and Other Neurodegenerative Brain Amyloidoses. NeuroMolecular Medicine, 2003, 4, 95-108.	3.6	52
276	A missense mutation (L166P) in DJâ€1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homoâ€oligomerization. Journal of Neurochemistry, 2003, 87, 1558-1567.	3.9	206
277	Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiology of Disease, 2003, 14, 303-317.	5.2	191
278	Caught in the Act. Neuron, 2003, 40, 453-456.	11.1	191
279	BAK Alters Neuronal Excitability and Can Switch from Anti- to Pro-Death Function during Postnatal Development. Developmental Cell, 2003, 4, 575-585.	7.8	119
280	37-kDa Laminin Receptor Precursor Modulates Cytotoxic Necrotizing Factor 1â€“mediated RhoA Activation and Bacterial Uptake. Journal of Biological Chemistry, 2003, 278, 16857-16862.	2.2	112
281	Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age. Journal of Biological Chemistry, 2003, 278, 48120-48128.	2.2	143
282	Nitric Oxide Protects Cardiac Sarcolemmal Membrane Enzyme Function and Ion Active Transport against Ischemia-induced Inactivation. Journal of Biological Chemistry, 2003, 278, 41798-41803.	2.2	40
283	Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. Journal of Biological Chemistry, 2003, 278, 13047-13055.	2.2	83
284	The Cast of Molecular Characters in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 80-92.	4.1	35
285	Apoptosis Inducing Factor and PARPâ€Mediated Injury in the MPTP Mouse Model of Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 132-139.	4.1	118
286	Human Î±-synuclein-harboring familial Parkinson's disease-linked Ala-53 â†' Thr mutation causes neurodegenerative disease with Î±-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8968-8973.	7.6	798
287	The Orphan Nuclear Receptor, Steroidogenic Factor 1, Regulates Neuronal Nitric Oxide Synthase Gene Expression in Pituitary Gonadotropes. Molecular Endocrinology, 2002, 16, 2828-2839.	2.6	30
288	Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. Journal of Cell Biology, 2002, 158, 507-517.	5.5	442

#	Article	IF	PR Citations
289	Lack of nitric oxide synthase depresses ion transporting enzyme function in cardiac muscle. Biochemical and Biophysical Research Communications, 2002, 294, 1030-1035.	2.1	35
290	Animal Models of PD. Neuron, 2002, 35, 219-222.	11.1	132
291	Poly(ADP-Ribose) Polymerase Impairs Early and Long-Term Experimental Stroke Recovery. Stroke, 2002, 33, 1101-1106.	6.0	127
292	The genetics of Parkinsonâ€™s disease. Current Neurology and Neuroscience Reports, 2002, 2, 439-446.	4.6	27
293	A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. Journal of Neurochemistry, 2002, 83, 186-192.	3.9	92
294	Neuroprotective and neurorestorative strategies for Parkinson's disease. Nature Neuroscience, 2002, 5, 1058-1061.	17.1	156
295	Gene therapy to the rescue in Parkinson's disease. Trends in Pharmacological Sciences, 2001, 22, 103-105.	11.8	4
296	Reduction of functional N-methyl-d-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. Journal of Neurochemistry, 2001, 76, 1386-1394.	3.9	8
297	Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. European Journal of Neuroscience, 2001, 13, 1683-1693.	3.6	88
298	Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Annals of Neurology, 2001, 50, 6-16.	6.3	85
299	Parkin ubiquitinates the Î±-synucleinâ€“interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Medicine, 2001, 7, 1144-1150.	39.5	733
300	Parkin: clinical aspects and neurobiology. Clinical Neuroscience Research, 2001, 1, 467-482.	1.0	16
301	Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics, 2001, 10, 919-926.	3.0	456
302	NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase. Journal of Neuroscience, 2000, 20, 8005-8011.	3.7	211
303	Stroke Outcome in Double-Mutant Antioxidant Transgenic Mice. Stroke, 2000, 31, 2685-2691.	6.0	44
304	Parkinson's disease: clinical manifestations and treatment. International Review of Psychiatry, 2000, 12, 263-269.	2.9	5
305	Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease. Neurobiology of Disease, 2000, 7, 240-250.	5.2	407
306	Neuronal ischaemic preconditioning. Trends in Pharmacological Sciences, 2000, 21, 423-424.	11.8	57

#	Article	IF	PR Citations
307	New Animal Models for Parkinson's Disease. Cell, 2000, 101, 115-118.	34.1	92
308	Mechanisms and Structural Determinants of HIV-1 Coat Protein, gp41-Induced Neurotoxicity. Journal of Neuroscience, 1999, 19, 64-71.	3.7	72
309	Circadian Locomotor Analysis of Male Mice Lacking the Gene for Neuronal Nitric Oxide Synthase (nNOSâ€"/â€"). Journal of Biological Rhythms, 1999, 14, 20-27.	2.9	29
310	Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine, 1999, 5, 1403-1409.	39.5	1,029
311	Overview of the Pathway and Functions of Nitric Oxide. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 1999, 00, .	0.0	0
312	Nuclear Targeting of Mutant Huntingtin Increases Toxicity. Molecular and Cellular Neurosciences, 1999, 14, 121-128.	2.2	179
313	Histochemical Analysis of Nitric Oxide Synthase by NADPH Diaphorase Staining. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 1999, 1, .	0.0	9
314	Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats. Stroke, 1999, 30, 1279-1285.	6.0	60
315	Free Radicals as Mediators of Neuronal Injury. Cellular and Molecular Neurobiology, 1998, 18, 667-682.	4.1	212
316	Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems. Neuroscientist, 1998, 4, 96-112.	4.5	21
317	NMDAR1 Glutamate Receptor Subunit Isoforms in Neostriatal, Neocortical, and Hippocampal Nitric Oxide Synthase Neurons. Journal of Neuroscience, 1998, 18, 1725-1734.	3.7	74
318	Manganese Superoxide Dismutase Protects nNOS Neurons from NMDA and Nitric Oxide-Mediated Neurotoxicity. Journal of Neuroscience, 1998, 18, 2040-2055.	3.7	264
319	Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Medicine, 1997, 3, 421-428.	39.5	362
320	Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nature Medicine, 1997, 3, 571-574.	39.5	148
321	Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Medicine, 1997, 3, 1089-1095.	39.5	1,020
322	NMDA-R1 subunit of the cerebral cortex co-localizes with neuronal nitric oxide synthase at pre- and postsynaptic sites and in spines. Brain Research, 1997, 750, 25-40.	2.5	102
323	Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone. Brain Research, 1997, 769, 66-70.	2.5	93
324	Effects of Nitric Oxide on Neuroendocrine Function and Behavior. Frontiers in Neuroendocrinology, 1997, 18, 463-491.	6.3	109

#	Article	IF	PR Citations
325	Nitric Oxide Synthase in Models of Focal Ischemia. Stroke, 1997, 28, 1283-1288.	6.0	590
326	NITRIC OXIDE SYNTHASE: Role as a Transmitter/Mediator in the Brain and Endocrine System. Annual Review of Medicine, 1996, 47, 219-227.	19.5	147
327	Nitric oxide neurotoxicity. Journal of Chemical Neuroanatomy, 1996, 10, 179-190.	2.0	473
328	NITRIC OXIDE ACTIONS IN NEUROCHEMISTRY. Neurochemistry International, 1996, 29, 97-110.	3.6	175
329	Nitric oxide synthase (NOS) in schizophrenia. Molecular and Chemical Neuropathology, 1996, 27, 275-284.	0.9	73
330	Neurobiology of Nitric Oxide. Critical Reviews in Neurobiology, 1996, 10, 291-316.	1.0	268
331	Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Annals of Neurology, 1995, 37, 115-118.	6.3	70
332	Effects of Central Inhibition of Nitric Oxide Synthase on Focal Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 779-786.	4.8	35
333	REVIEW â– : Nitric Oxide: Actions and Pathological Roles. Neuroscientist, 1995, 1, 7-18.	4.5	101
334	Widespread expression of Huntington's disease gene (IT15) protein product. Neuron, 1995, 14, 1065-1074.	11.1	500
335	Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Annals of Neurology, 1994, 36, 778-786.	6.3	537
336	Nitric oxide mediates the formation of synaptic connections in developing and regenerating olfactory receptor neurons. Neuron, 1994, 13, 289-299.	11.1	233
337	gp120 neurotoxicity in primary cortical cultures. Advances in Neuroimmunology, 1994, 4, 167-173.	1.7	25
338	Secondary mechanisms in neuronal trauma. Current Opinion in Neurology, 1994, 7, 510-516.	3.8	145
339	Molecular Mechanisms of Nitric Oxide Actions in the Brain^a. Annals of the New York Academy of Sciences, 1994, 738, 76-85.	4.1	106
340	Possible Origins and Distribution of Immunoreactive Nitric Oxide Synthase-Containing Nerve Fibers in Cerebral Arteries. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 70-79.	4.8	377
341	Neurotransmitter release regulated by nitric oxide in PC-12 cells and brain synaptosomes. Current Biology, 1993, 3, 749-754.	3.6	110
342	Enhanced expression of nitric oxide synthase by rat retina following pterygopalatine parasympathetic denervation. Brain Research, 1993, 631, 83-88.	2.5	52

#	Article	IF	PR Citations
343	Targeted disruption of the neuronal nitric oxide synthase gene. Cell, 1993, 75, 1273-1286.	34.1	1,345
344	Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. Annals of Neurology, 1992, 32, 818-820.	6.3	178
345	Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants. Brain Research, 1991, 540, 145-152.	2.5	22
346	Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron, 1991, 7, 615-624.	11.1	1,402
347	Thrombotic microangiopathy isolated to the central nervous system. Annals of Neurology, 1991, 30, 843-846.	6.3	2
348	Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. Brain Research Bulletin, 1990, 25, 903-912.	3.5	37
349	Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology, 1988, 94, 141-143.	2.9	62
350	Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. Life Sciences, 1988, 42, 1933-1939.	4.7	80
351	Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase. Brain Research Bulletin, 1988, 20, 447-459.	3.5	69
352	Presynaptic and postsynaptic D1 dopamine receptors in the nigrostriatal system of the rat brain: a quantitative autoradiographic study using the selective D1 antagonist [3H]SCH 23390. Brain Research, 1987, 408, 205-209.	2.5	84
353	Chronic administration of sertraline, a selective serotonin uptake inhibitor, decreased the density of Î²-adrenergic receptors in rat frontoparietal cortex. Brain Research, 1987, 421, 377-381.	2.5	30
354	Evidence that [3H]forskolin binding in the substantia nigra is intrinsic to a striatal-nigral projection: An autoradiographic study of rat brain. Neuroscience Letters, 1987, 73, 114-118.	1.9	27
355	Autoradiographic Evidence of [3H]SCH 23390 Binding Site; in Human Prefrontal Cortex (Brodmann's) Tj ETQq1 1 0.784314 rgBT /Ov	3.9	34
356	Quantitative autoradiographic evidence for axonal transport of imipramine receptors in the central nervous system of the rat. Neuroscience Letters, 1985, 55, 261-266.	1.9	32
357	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. ELife, 0, 10, .	1.6	24
358	Unraveling the tau puzzle: a review of mechanistic targets and therapeutic interventions to prevent tau pathology in Alzheimerâ€™s disease. , 0, 3, .		4